TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis
Brief Summary: This was a randomized, double-blind study comparing the efficacy and safety of ruxolitinib (INCB018424) tablets to matching placebo tablets in patients diagnosed with Myelofibrosis (either Primary Myelofibrosis (PMF) or Post-Polycythemia Vera Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia Myelofibrosis (PET-MF).


Options:
A: Arm Label: Ruxolitinib; Type: EXPERIMENTAL; Interventions: Drug: Ruxolitinib | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Ruxolitinib, Drug: Placebo | Intervention Type: DRUG; Name: Ruxolitinib; Assigned to Arm(s): Placebo, Ruxolitinib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Lenalidomide + Prednisone; Type: EXPERIMENTAL; Interventions: Drug: Lenalidomide, Drug: Prednisone | Intervention Type: DRUG; Name: Lenalidomide; Assigned to Arm(s): Lenalidomide + Prednisone | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Lenalidomide + Prednisone
C: Arm Label: Ruxolitinib; Type: EXPERIMENTAL; Interventions: Drug: Ruxolitinib | Intervention Type: DRUG; Name: Ruxolitinib; Assigned to Arm(s): Ruxolitinib
D: Arm Label: CEP-701; Type: EXPERIMENTAL; Interventions: Drug: CEP-701 | Intervention Type: DRUG; Name: CEP-701; Assigned to Arm(s): CEP-701

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Physiology Study Investigating the Effects of Supplementation and Depletion of Iron on Hypoxia-related Pulmonary Hypertension
Brief Summary: The study hypothesis is that body iron levels are important in determining the increase in lung blood pressure that occurs in response to low oxygen levels. The purpose of this study is to determine whether this is true at high altitude, where oxygen levels are low.


Options:
A: Arm Label: Ferinject (ferric carboxymaltose); Type: EXPERIMENTAL; Interventions: Drug: Ferinject (ferric carboxymaltose) | Arm Label: Standard of Care; Type: OTHER; Interventions: Other: Standard of Care | Intervention Type: DRUG; Name: Ferinject (ferric carboxymaltose); Assigned to Arm(s): Ferinject (ferric carboxymaltose) | Intervention Type: OTHER; Name: Standard of Care; Assigned to Arm(s): Standard of Care
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Ferinject ® (Ferric carboxymaltose) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal saline (0.9%) | Intervention Type: DRUG; Name: Ferinject ® (Ferric carboxymaltose); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Normal saline (0.9%); Assigned to Arm(s): 2
C: Arm Label: Oral iron supplement every day for 14 days; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Daily administration of 60 mg iron in form of ferrous sulphate capsules for 14 consecutive days | Arm Label: Oral iron supplement every second day for 28 days; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Administrations of 60 mg iron in form of ferrous sulphate capsules on every second day for 28 days | Intervention Type: DIETARY_SUPPLEMENT; Name: Daily administration of 60 mg iron in form of ferrous sulphate capsules for 14 consecutive days; Assigned to Arm(s): Oral iron supplement every day for 14 days | Intervention Type: DIETARY_SUPPLEMENT; Name: Administrations of 60 mg iron in form of ferrous sulphate capsules on every second day for 28 days; Assigned to Arm(s): Oral iron supplement every second day for 28 days
D: Arm Label: CMS - placebo first; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Venesection, Drug: Iron sucrose, Drug: Normal saline | Arm Label: CMS - iron; Type: EXPERIMENTAL; Interventions: Procedure: Venesection, Drug: Iron sucrose, Drug: Normal saline | Arm Label: SLR - placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal saline | Arm Label: SLR - iron; Type: EXPERIMENTAL; Interventions: Drug: Iron sucrose | Intervention Type: DRUG; Name: Iron sucrose; Assigned to Arm(s): SLR - iron | Intervention Type: DRUG; Name: Normal saline; Assigned to Arm(s): SLR - placebo | Intervention Type: PROCEDURE; Name: Venesection; Assigned to Arm(s): CMS - iron, CMS - placebo first | Intervention Type: DRUG; Name: Iron sucrose; Assigned to Arm(s): CMS - iron, CMS - placebo first | Intervention Type: DRUG; Name: Normal saline; Assigned to Arm(s): CMS - iron, CMS - placebo first

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Randomized, Multi-center, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial to Study the Safety, Tolerability and Efficacy of MK0869/Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With High-Dose Cisplatin
Brief Summary: This study will demonstrate and confirm the efficacy and safety of MK0869 for the treatment of chemotherapy-induced nausea and vomiting in Chinese patients.


Options:
A: Arm Label: ramosetron, aprepitant, dexamethasone; Type: EXPERIMENTAL; Interventions: Drug: ramosetron | Arm Label: ondansetron, aprepitant, dexamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: ondansetron | Intervention Type: DRUG; Name: ramosetron; Assigned to Arm(s): ramosetron, aprepitant, dexamethasone | Intervention Type: DRUG; Name: ondansetron; Assigned to Arm(s): ondansetron, aprepitant, dexamethasone
B: Intervention Type: DRUG; Name: MK0869, aprepitant / Duration of Treatment: 3 days; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Comparator: ondansetron / Duration of Treatment: 4 days; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: palonosetron | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: granisetron hydrochloride | Intervention Type: DRUG; Name: palonosetron; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: granisetron hydrochloride; Assigned to Arm(s): 2
D: Arm Label: Aprepitant (MK-0869); Type: EXPERIMENTAL; Interventions: Drug: aprepitant, Drug: granisetron, Drug: dexamethasone | Arm Label: Standard Therapy; Type: PLACEBO_COMPARATOR; Interventions: Drug: Comparator: Placebo to aprepitant, Drug: dexamethasone, Drug: granisetron | Intervention Type: DRUG; Name: aprepitant; Assigned to Arm(s): Aprepitant (MK-0869) | Intervention Type: DRUG; Name: Comparator: Placebo to aprepitant; Assigned to Arm(s): Standard Therapy | Intervention Type: DRUG; Name: dexamethasone; Assigned to Arm(s): Standard Therapy | Intervention Type: DRUG; Name: granisetron; Assigned to Arm(s): Aprepitant (MK-0869), Standard Therapy | Intervention Type: DRUG; Name: dexamethasone; Assigned to Arm(s): Aprepitant (MK-0869)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Immunogenicity and Safety of Multiple Formulations of an A/H1N1 Pandemic Vaccine in Healthy Subjects Aged 6 Months to 9 Years
Brief Summary: The purpose of the study is to evaluate different doses of the Influenza A/H1N1 pandemic vaccine in toddlers and children.

Primary Objectives:

* To describe the immunogenicity of the candidate vaccines after each injection.
* To describe the safety of the candidate vaccines after each injection.


Options:
A: Arm Label: A/H1N1 Vaccine Group 1; Type: EXPERIMENTAL; Interventions: Biological: Monovalent Subvirion A/H1N1 Influenza vaccine | Arm Label: A/H1N1 Vaccine Group 2; Type: EXPERIMENTAL; Interventions: Biological: Monovalent Subvirion A/H1N1 Influenza vaccine | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Normal saline solution (placebo) | Intervention Type: BIOLOGICAL; Name: Monovalent Subvirion A/H1N1 Influenza vaccine; Assigned to Arm(s): A/H1N1 Vaccine Group 1 | Intervention Type: BIOLOGICAL; Name: Monovalent Subvirion A/H1N1 Influenza vaccine; Assigned to Arm(s): A/H1N1 Vaccine Group 2 | Intervention Type: BIOLOGICAL; Name: Normal saline solution (placebo); Assigned to Arm(s): Placebo Group
B: Arm Label: MEDI3414 [Influenza A (H1N1) vaccine]; Type: ACTIVE_COMPARATOR; Interventions: Biological: MEDI3414 [Influenza A(H1N1) live attenuated, intranasal] | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: MEDI3414 [Influenza A(H1N1) live attenuated, intranasal]; Assigned to Arm(s): MEDI3414 [Influenza A (H1N1) vaccine] | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: BIOLOGICAL; Name: CAIV-T; Assigned to Arm(s): N/A
D: Arm Label: MEDI3414 [Influenza A (H1N1) vaccine]; Type: EXPERIMENTAL; Interventions: Biological: MEDI3414 [Influenza A/H1N1 live attenuated, intranasal] | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: BIOLOGICAL; Name: MEDI3414 [Influenza A/H1N1 live attenuated, intranasal]; Assigned to Arm(s): MEDI3414 [Influenza A (H1N1) vaccine] | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Immunogenicity and Safety of Multiple Formulations of an A/H1N1 Pandemic Vaccine in Healthy Subjects Aged 6 Months to 9 Years
Brief Summary: The purpose of the study is to evaluate different doses of the Influenza A/H1N1 pandemic vaccine in toddlers and children.

Primary Objectives:

* To describe the immunogenicity of the candidate vaccines after each injection.
* To describe the safety of the candidate vaccines after each injection.


Options:
A: Arm Label: A/H1N1 Vaccine Group 1; Type: EXPERIMENTAL; Interventions: Biological: Monovalent Subvirion A/H1N1 Influenza vaccine | Arm Label: A/H1N1 Vaccine Group 2; Type: EXPERIMENTAL; Interventions: Biological: Monovalent Subvirion A/H1N1 Influenza vaccine | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Normal saline solution (placebo) | Intervention Type: BIOLOGICAL; Name: Monovalent Subvirion A/H1N1 Influenza vaccine; Assigned to Arm(s): A/H1N1 Vaccine Group 1 | Intervention Type: BIOLOGICAL; Name: Monovalent Subvirion A/H1N1 Influenza vaccine; Assigned to Arm(s): A/H1N1 Vaccine Group 2 | Intervention Type: BIOLOGICAL; Name: Normal saline solution (placebo); Assigned to Arm(s): Placebo Group
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: Inactivated influenza vaccine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Biological: Saline | Intervention Type: BIOLOGICAL; Name: Inactivated influenza vaccine; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Saline; Assigned to Arm(s): 2
C: Arm Label: Influenza; Type: EXPERIMENTAL; Interventions: Biological: Influenza vaccination | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Biological: Hepatitis A Vaccine | Intervention Type: BIOLOGICAL; Name: Influenza vaccination; Assigned to Arm(s): Influenza | Intervention Type: BIOLOGICAL; Name: Hepatitis A Vaccine; Assigned to Arm(s): Control
D: Intervention Type: BIOLOGICAL; Name: CAIV-T; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Periconceptional Iron Supplementation on Iron and Folate Indicators Among Pregnant and Non-pregnant Women in Rural Bangladesh.
Brief Summary: The investigators hypothesize that periconceptional iron supplementation to married, nulliparous women in rural Bangladesh will significantly reduce anemia and improve hemoglobin concentrations before and during pregnancy.


Options:
A: Arm Label: Pregnant Women; Type: N/A; Interventions: Drug: Traditional Tablet, Drug: Chewable tablets, Drug: Unflavoured Powder, Drug: Flavoured Powder | Intervention Type: DRUG; Name: Traditional Tablet; Assigned to Arm(s): Pregnant Women | Intervention Type: DRUG; Name: Chewable tablets; Assigned to Arm(s): Pregnant Women | Intervention Type: DRUG; Name: Unflavoured Powder; Assigned to Arm(s): Pregnant Women | Intervention Type: DRUG; Name: Flavoured Powder; Assigned to Arm(s): Pregnant Women
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Ferrous fumarate (iron), Dietary Supplement: folic acid | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: folic acid | Intervention Type: DIETARY_SUPPLEMENT; Name: Ferrous fumarate (iron); Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: folic acid; Assigned to Arm(s): 1, 2
C: Intervention Type: DIETARY_SUPPLEMENT; Name: Daminaide 995 - SuppleFem Sprinkles; Assigned to Arm(s): N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Materna; Assigned to Arm(s): N/A
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Other: Nutritional Counselling and Education | Arm Label: B; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Micronutrient Supplementation without Zinc | Arm Label: C; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Micronutrient Supplementation with Zinc | Intervention Type: DIETARY_SUPPLEMENT; Name: Micronutrient Supplementation without Zinc; Assigned to Arm(s): B | Intervention Type: DIETARY_SUPPLEMENT; Name: Micronutrient Supplementation with Zinc; Assigned to Arm(s): C | Intervention Type: OTHER; Name: Nutritional Counselling and Education; Assigned to Arm(s): A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Periconceptional Iron Supplementation on Iron and Folate Indicators Among Pregnant and Non-pregnant Women in Rural Bangladesh.
Brief Summary: The investigators hypothesize that periconceptional iron supplementation to married, nulliparous women in rural Bangladesh will significantly reduce anemia and improve hemoglobin concentrations before and during pregnancy.


Options:
A: Intervention Type: DRUG; Name: Nutritional supplements; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Ferrous fumarate (iron), Dietary Supplement: folic acid | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: folic acid | Intervention Type: DIETARY_SUPPLEMENT; Name: Ferrous fumarate (iron); Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: folic acid; Assigned to Arm(s): 1, 2
C: N/A
D: Arm Label: Early umbilical cord clamping (control); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Delayed umbilical cord clamping; Type: EXPERIMENTAL; Interventions: Procedure: Delayed umbilical cord clamping | Intervention Type: PROCEDURE; Name: Delayed umbilical cord clamping; Assigned to Arm(s): Delayed umbilical cord clamping

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Periconceptional Iron Supplementation on Iron and Folate Indicators Among Pregnant and Non-pregnant Women in Rural Bangladesh.
Brief Summary: The investigators hypothesize that periconceptional iron supplementation to married, nulliparous women in rural Bangladesh will significantly reduce anemia and improve hemoglobin concentrations before and during pregnancy.


Options:
A: Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Folate; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Nutritional supplements; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Ferrous fumarate (iron), Dietary Supplement: folic acid | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: folic acid | Intervention Type: DIETARY_SUPPLEMENT; Name: Ferrous fumarate (iron); Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: folic acid; Assigned to Arm(s): 1, 2
D: Arm Label: Folic acid; Type: OTHER; Interventions: Dietary Supplement: Folic acid | Arm Label: Placebo; Type: OTHER; Interventions: Other: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Folic acid; Assigned to Arm(s): Folic acid | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Periconceptional Iron Supplementation on Iron and Folate Indicators Among Pregnant and Non-pregnant Women in Rural Bangladesh.
Brief Summary: The investigators hypothesize that periconceptional iron supplementation to married, nulliparous women in rural Bangladesh will significantly reduce anemia and improve hemoglobin concentrations before and during pregnancy.


Options:
A: Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Folate; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: "video doctor," computer module | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: "video doctor," computer module | Intervention Type: BEHAVIORAL; Name: "video doctor," computer module; Assigned to Arm(s): 1, 2
C: Arm Label: Folic acid; Type: OTHER; Interventions: Dietary Supplement: Folic acid | Arm Label: Placebo; Type: OTHER; Interventions: Other: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Folic acid; Assigned to Arm(s): Folic acid | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Ferrous fumarate (iron), Dietary Supplement: folic acid | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: folic acid | Intervention Type: DIETARY_SUPPLEMENT; Name: Ferrous fumarate (iron); Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: folic acid; Assigned to Arm(s): 1, 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Remote Ischemic Preconditioning on Cognitive Function After Off-Pump Coronary Artery Bypass Graft
Brief Summary: The aim of this study is to evaluate the effects of remote ischemic preconditioning on cognitive function in patients undergoing off-pump coronary artery bypass graft.


Options:
A: Arm Label: RIPC; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Remote Ischemic Preconditioning | Arm Label: CONTROL; Type: PLACEBO_COMPARATOR; Interventions: Other: Control | Intervention Type: PROCEDURE; Name: Remote Ischemic Preconditioning; Assigned to Arm(s): RIPC | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): CONTROL
B: Arm Label: Remote ischemic preconditioning; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Remote ischemic preconditioning | Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Procedure: Control | Intervention Type: PROCEDURE; Name: Remote ischemic preconditioning; Assigned to Arm(s): Remote ischemic preconditioning | Intervention Type: PROCEDURE; Name: Control; Assigned to Arm(s): Control
C: Arm Label: Remote ischemic preconditioning; Type: ACTIVE_COMPARATOR; Interventions: Procedure: remote ischemic preconditioning | Arm Label: control; Type: PLACEBO_COMPARATOR; Interventions: Procedure: remote ischemic preconditioning | Intervention Type: PROCEDURE; Name: remote ischemic preconditioning; Assigned to Arm(s): Remote ischemic preconditioning, control
D: Arm Label: ExerciseTr; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise training | Arm Label: Remote ischemic preconditioning group; Type: EXPERIMENTAL; Interventions: Procedure: remote ischemic preconditioning | Arm Label: Control patient group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise training; Assigned to Arm(s): ExerciseTr | Intervention Type: PROCEDURE; Name: remote ischemic preconditioning; Assigned to Arm(s): Remote ischemic preconditioning group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of VX-770 in Subjects Aged 12 Years and Older With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation
Brief Summary: The purpose of this study was to evaluate the safety and efficacy of ivacaftor in participants with cystic fibrosis (CF) who were aged 12 years or older and were homozygous for the F508del-CF transmembrane conductance regulator (CFTR) mutation. Ivacaftor is a potent and selective CFTR potentiator of wild-type, G551D, F508del, and R117H forms of human CFTR protein. Potentiators are pharmacological agents that increase the chloride ion transport properties of the channel in the presence of cyclic adenosine monophosphate (AMP)-dependent protein kinase A (PKA) activation.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Ivacaftor, Drug: Placebo | Arm Label: Ivacaftor; Type: EXPERIMENTAL; Interventions: Drug: Ivacaftor | Intervention Type: DRUG; Name: Ivacaftor; Assigned to Arm(s): Ivacaftor, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Ivacaftor; Type: EXPERIMENTAL; Interventions: Drug: Ivacaftor | Arm Label: Observational; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Ivacaftor; Assigned to Arm(s): Ivacaftor
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: VX-809, 25 mg; Type: EXPERIMENTAL; Interventions: Drug: VX-809 | Arm Label: VX-809, 50 mg; Type: EXPERIMENTAL; Interventions: Drug: VX-809 | Arm Label: VX-809, 100 mg; Type: EXPERIMENTAL; Interventions: Drug: VX-809 | Arm Label: VX-809, 200 mg; Type: EXPERIMENTAL; Interventions: Drug: VX-809 | Intervention Type: DRUG; Name: VX-809; Assigned to Arm(s): VX-809, 100 mg, VX-809, 200 mg, VX-809, 25 mg, VX-809, 50 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: ivacaftor-placebo; Type: EXPERIMENTAL; Interventions: Drug: ivacaftor, Drug: Placebo | Arm Label: placebo-ivacaftor; Type: EXPERIMENTAL; Interventions: Drug: ivacaftor, Drug: Placebo | Intervention Type: DRUG; Name: ivacaftor; Assigned to Arm(s): ivacaftor-placebo, placebo-ivacaftor | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): ivacaftor-placebo, placebo-ivacaftor

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Minimization of Surgical Site Infections for Pts Undergoing Colorectal Surgery
Brief Summary: This is a comparison, at this VA Hospital, of standard operating room management in colorectal surgery to a more rigid management using an additional five previously tested treatments to determine if this changes the rate of post operative wound infections.


Options:
A: Arm Label: Oral Antibiotics; Type: N/A; Interventions: Drug: Paromomycin Sulfate Powder | Arm Label: iv Antibiotics; Type: N/A; Interventions: N/A | Intervention Type: DRUG; Name: Paromomycin Sulfate Powder; Assigned to Arm(s): Oral Antibiotics
B: Arm Label: oral antibiotics+mechanical bowel preparation; Type: EXPERIMENTAL; Interventions: Drug: Neomycin,metronidazole | Arm Label: simple mechanical bowel preparation; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Neomycin,metronidazole; Assigned to Arm(s): oral antibiotics+mechanical bowel preparation
C: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: standard operating management | Intervention Type: PROCEDURE; Name: standard operating management; Assigned to Arm(s): 2
D: Arm Label: Standard treatment; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Selective decontamination of the digestive tract (SDD); Type: EXPERIMENTAL; Interventions: Drug: Selective decontamination of the digestive tract (SDD) (colistin sulfate, tobramycin, amphotericin B) | Intervention Type: DRUG; Name: Selective decontamination of the digestive tract (SDD) (colistin sulfate, tobramycin, amphotericin B); Assigned to Arm(s): Selective decontamination of the digestive tract (SDD)

Answer: C